Summary
Vascular smooth muscle cells (vSMCs) are highly heterogeneous across different vascular beds. This is partly dictated by their developmental origin but also their position in the vascular tree, reflected in their differential responses to vasoactive agonists depending on which arteriolar or venular segment they are located. Functional assays are necessary to capture this heterogeneity in vitro since there are no markers that distinguish subtypes. Here we describe methods for determining real-time intracellular Ca2+ release and contraction in vSMCs of neural crest origin differentiated from human induced pluripotent stem cells using multiple protocols, and compare these with primary human brain vascular pericytes and smooth muscle cells. Open-source software was adapted for automated high-density analysis of Ca2+-release kinetics and contraction by tracking individual cells. Simultaneous measurements on hundreds of cells revealed heterogeneity in responses to vasoconstrictors that would likely be overlooked using manual low-throughput assays or marker expression.
Keywords: human induced pluripotent stem cells (hiPSCs), vascular smooth muscle cells (vSMCs), neural crest-derived vascular smooth muscle cells (NC-SMCs), real-time intracellular Ca2+ release in vSMCs, microfluidics, contraction, cell tracking, automated image analysis, CellProfiler, LC_Pro plugin for ImageJ
Graphical Abstract
Highlights
-
•
Microfluidic assay for real-time Ca2+ release in hiPSC-derived vSMCs
-
•
Automated Ca2+ release and contraction analysis in hiPSC-derived vSMCs
-
•
Side-by-side comparison of hiPSC-derived vSMCs with human brain pericytes and vSMCs
In this article, Orlova and colleagues describe methods for real-time intracellular Ca2+ release and contraction in vascular smooth muscle cells differentiated from human induced pluripotent stem cells. Open-source software adapted for automated high-density analysis and simultaneous measurements of hundreds of cells revealed heterogeneity in responses to vasoconstrictors that would likely be overlooked using standard low-throughput assays or marker expression.
Introduction
Vascular smooth muscle cell (vSMC) dysfunction is associated with many diseases ranging from atherosclerosis and hypertension to cerebrovascular disorders (Owens et al., 2004, Sinha and Santoro, 2018). Developmentally, vSMCs originate from multiple lineages including mesoderm and neural crest, the primary source of vSMCs in the cerebral vasculature (Majesky, 2007). Human induced pluripotent stem cells (hiPSCs) have been shown to be an excellent source of vSMCs of various developmental origins (Cheung et al., 2014, Cheung et al., 2012, Granata et al., 2017), presenting new opportunities for disease modeling and drug discovery using patient-specific cells. Despite improvements in protocols for vSMC differentiation, assays for their automated functional characterization have lagged behind. vSMCs, like striated cardiac and skeletal myocytes, are contractile and their contractile responses are correlated with global changes in intracellular Ca2+ (Wray et al., 2005). vSMCs in situ exhibit rapid intracellular Ca2+ release in response to vasoconstrictors. The initial response occurs within ∼10 s and is followed by prolonged wave-like oscillations as a result of intracellular Ca2+ release and reuptake (Borysova et al., 2013). Cultured vSMCs exhibit profound heterogeneity in their responses to vasoconstrictors. However, most studies of intracellular Ca2+ release do not capture this heterogeneity in responses. Intracellular Ca2+ release is typically measured as a low-throughput assessment of selected regions of interest that may not represent the whole cell population and its intrinsic heterogeneity. In addition, even though the flow-cytometry method to determine intracellular Ca2+ is high-throughput, it lacks physiological relevance and does not allow tracking of Ca2+ flux in individual cells over time so that signal shape parameters cannot be derived. High-throughput, robust, and standardized assays that accurately assess vSMC functionality would be of value in monitoring drug responses and disease phenotypes.
Here, we developed functional assays and an automated quantification framework for intracellular Ca2+ release and contraction in vSMCs. vSMCs were differentiated via neural crest intermediates from three independent healthy hiPSC lines, using various protocols based on previously published methods (Cheung et al., 2012, Dash et al., 2016, Granata et al., 2017, Wanjare et al., 2013, Wanjare et al., 2014). The functionality of these hiPSC-derived vSMCs was compared side by side with primary human brain vascular pericytes (HBVPs) and human brain vSMCs (HBVSMCs) using a set of well-established vasoconstrictors. Heterogeneity in responses of both hiPSC-derived and primary vSMCs was observed that would likely be overlooked using manual low-throughput assays.
Results
Differentiation of Neural Crest Cells from hiPSCs
Bone morphogenetic protein, WNT, and fibroblast growth factor (FGF) signaling are known to be important for the induction of neural crest cells (NCCs) from human pluripotent stem cells (hPSCs) (Cheung et al., 2014, Fukuta et al., 2014, Hackland et al., 2017, Huang et al., 2016, Lee et al., 2007, Leung et al., 2016, Menendez et al., 2011). Since the efficiency of NCC induction in hiPSCs varies, even in defined medium, we tested several protocols in parallel and found that the combination of the transforming growth factor β (TGF-β) inhibitor SB431542 (10 μM), the small molecular WNT activator CHIR99021 (1 μM), and basic FGF (10 ng/mL) using a protocol adapted from previous work (Cheung et al., 2014, Fukuta et al., 2014) was the most robust in defined BPEL (BSA polyvinylalcohol essential lipids) medium (Ng et al., 2008) (Figures 1A, 1B, and S1A). Fluorescence-activated cell sorting (FACS) analysis on day 12 of differentiation showed that 40%–50% of cells were positive for neural crest markers (NGFR and HNK1) and negative for pluripotency markers (TRA-1-60 and SOX2) (Figures S1B and S1C). Importantly, the proportion of NGFR+/HNK1+/TRA-1-60−/SOX2− cells could be enriched to ∼80%–90% at passage 1 (P1) by simple mechanical elimination of the cells in the center of the colonies. FACS analysis showed that NCCs (NGFR+/HNK1+/TRA-1-60−/SOX2−) maintained their phenotype up to P7 (Figure S1D). Nuclear localization of neural crest markers, such as TFAP2A, SOX9, and SOX10, as well as downregulation of SOX2 was confirmed by immunofluorescence (Figure 1D). Successful derivation of NCCs using this method was shown in three different hiPSC lines (FLB243, LUMC054, and NCRM1) with comparable high efficiencies (Figure 1E). Notably, NCCs could be cryopreserved at P3 and used as a cell source for further differentiation into SMCs.
Differentiation of vSMCs from hiPSC-Derived NCCs
We next differentiated NCCs into vSMCs (NC-SMCs) using previously described protocols, with some modifications as shown in Figure 1F (Cheung et al., 2012, Dash et al., 2016, Granata et al., 2017, Wanjare et al., 2014, Wanjare et al., 2013). We also included HBVPs and HBVSMCs as primary human perivascular cells of the same developmental origin for comparison. Analysis of relative gene expression showed downregulation of neural crest markers, such as TFAP2A, SOX9, SOX10, and PAX3, and upregulation of SMC contractile markers such as ACTA2, CNN1, SM22, and MYH11, in NC-SMCs compared with NCCs; however, expression of MYH11 remained relatively low (Figure 1G). Expression of contractile SMC markers was similar in all NC-SMCs independent of the differentiation protocol used and was higher than in primary HBVPs and HBVSMCs (Figure 1G). Expression of contractile proteins was confirmed by immunofluorescence (Figures 1H and S1F).
Quantitative Assessment of Intracellular Ca2+ Release in NC-SMCs and Primary vSMCs
Intracellular Ca2+ release was determined in NC-SMCs (differentiated with protocols A to E) and HBVPs and HBVSMCs, using an experimental setup that combined microfluidics and live-cell imaging (Video S1). Fluo-4 was used as an indicator to monitor changes in intracellular Ca2+ over time in hundreds of SMCs simultaneously (Figure S2A). Control stimulation was performed using medium only without the addition of the drug (blue box in Figure S2B), followed by drug administration (yellow box in Figure S2B). For quantitative analysis of Ca2+ activity recordings, an algorithm for automated identification and analysis of regions of interest (ROIs) in two-dimensional image sequences was used (Francis et al., 2012). Intracellular Ca2+ release was examined upon stimulation with the vasoconstrictor endothelin-I (ET-I) (0.1 μM and 1 μM) (Figures 2A, 2B, and S2C). Notably, NC-SMCs differentiated using protocols C and D showed lower responses to ET-I (0.1 μM, Figure 2A and 1 μM, Figure S2C) and had a considerably lower expression level of ET-I receptor (EDNRA), while expression of other receptors and ion channels was comparable (Figure S1E). NC-SMCs differentiated using protocols A, B, and E, as well as HBVSMCs, showed substantial variation in the number of Ca2+ events with a single or main peak (MP) and recurrent secondary peaks (SPs), while the vast majority of NC-SMCs differentiated using protocols C and D, as well as HBVPs, had only one MP (Figures 2B and 2C).
To describe and compare shapes of Ca2+ signals, we derived kinetic parameters of the average fluorescence intensity of ROIs normalized to baseline over time (F/F0). Time to peak, decay, and duration were measured at the half-maximum level (F/F0)max (Figure 2D). Ca2+ kinetic parameters showed substantial heterogeneity in all vSMCs examined (Figure 2E). Distributions of time to peak and decay were positively skewed while the distribution of duration was close to Gaussian and the number of events within ROI was distributed exponentially. Bimodal histograms of time to peak in NC-SMCs differentiated using protocols C, D and HBVPs revealed subpopulations with slower and faster Ca2+ release and reuptake (Figure 2E).
To compare population histograms quantitatively, we used a method reported previously that allows measurement of the difference between two populations (James et al., 2011). A schematic illustration of the method is shown in Figure 3A. The method is based on a simple metric that estimates the extent of divergence of two histograms reflected by a value D, which is close to zero if histograms are largely overlapping and equals 1 when histograms do not overlap at all (Figure 3A, Supplemental Experimental Procedures, and Equation 3). We classified ranges of D values into three categories that reflect the extent of histogram divergence for each type of measurement: events within ROI (low: D = 0.0–0.1; moderate: D = 0.11–0.2; high: D = 0.21–1.0) and kinetic parameters of Ca2+ peaks (low: D = 0.0–0.3; moderate: D = 0.31–0.45; high: D = 0.46–1.0). The rationale for setting different ranges for these types of measurement was based on corresponding intrapopulation D values between either technical replicates or independent biological experiments (data not shown).
When comparing the number of Ca2+ events within ROI, we obtained low D values between HBVPs and NC-SMCs differentiated with protocols C and D (D = 0.08 and D = 0.05, respectively) but moderate to high D values between HBVPs and NC-SMCs differentiated with protocols A, B, and E and HBVSMCs (D = 0.19–0.23) (Figure 3B). HBVSMCs showed low D values compared with NC-SMCs differentiated with protocols A, B, and E (D = 0.02–0.06) and moderate to high D values compared with NC-SMCs differentiated with protocol C and D and HBVPs (D = 0.19–0.27) (Figure 3B). Comparison of HBVSMCs with all NC-SMCs showed moderate to high D values of kinetic parameters of MP (time to peak: D = 0.32–0.47; decay: D = 0.35–0.63; duration: D = 0.68–0.83) (Figure 3C) but low to moderate D values of SPs in NC-SMCs differentiated with protocols A, B, and E (time to peak: D = 0.30–0.41; decay: D = 0.19–0.35; duration: D = 0.30–0.43) (Figures 3D and 3E). Predominantly low to moderate D values of kinetic parameters of MP were obtained on comparing HBVPs and NC-SMCs (time to peak: D = 0.17–0.51; decay: D = 0.14–0.32; duration: D = 0.14–0.36) (Figure 3C).
Quantitative Assessment of Contraction in NC-SMCs and Primary vSMCs
To assess vSMC contraction, we developed an automated pipeline that included primary object identification and object tracking based on pixel intensity (Figure 4A and Video S2). This allowed image processing to be automated and tracking of changes in the surface area of individual cells, with unbiased processing of large numbers of cells captured in given fields of view. Individual cell contraction was calculated as relative change of cell-surface area (ΔS/S, in percent) (Supplemental Experimental Procedures; Equations 1 and 2) and plotted as population histograms. Contraction of NC-SMCs differentiated using protocols A to E, HBVPs, and HBVSMCs upon stimulation with vasoconstrictor ET-I or control stimulation (medium only, black histograms) was next evaluated (Figure 4B). Although we did observe fluctuations in cell-surface area upon control stimulation, the distributions had median values close to zero and a small dispersion, which was significantly different compared with stimulation with vasoconstrictor ET-I (0.1 μM) (p < 0.0001) (Figure 4B, box plots). Notably, NC-SMCs differentiated using protocols C and D showed the lowest relative cell-surface area decrease (Figure 4B). Stimulation with a higher concentration of ET-I (1 μM) did not increase contraction values (Figure S2D). We next compared population histograms of relative cell area decrease in all conditions, using analysis of difference described above (Figure 3A). We classified ranges of D values of contraction ΔS/S into three categories (low: D = 0.0–0.25; moderate: D = 0.26–0.50; high: D = 0.51–1.0) to reflect the extent of the differences. NC-SMCs differentiated using protocol E had the lowest difference compared with HBVSMCs (D = 0.11) and HBVPs (D = 0.21) among all NC-SMCs (Figure 4C) and showed high median relative cell-surface area decrease (Figure 4B, box plots). NC-SMCs differentiated using protocols A to D showed moderate differences compared with HBVPs (D = 0.28–0.37), moderate to high differences compared with HBVSMCs (D = 0.41–0.51), and low median relative cell-surface area decreases. Additionally, side-by-side assessment of contraction upon stimulation with ET-I (0.1 μM) in NC-SMCs differentiated using protocols A to E from three independent hiPSC lines showed reproducible decreases in relative cell-surface area, with NC-SMCs differentiated using protocol E being the most contractile (Figure 4D).
Comparative Analysis of Intracellular Ca2+ Release and Contraction in NC-SMCs
To evaluate the robustness and functional reproducibility of the 12-day protocol A, we evaluated Ca2+ release and contraction of NC-SMCs differentiated from three independent hiPSC lines and compared this with cells derived using protocol B. Intracellular Ca2+ release in NC-SMCs differentiated using either protocol was examined upon stimulation with various vasoconstrictors, such as ET-I (0.1 μM), carbachol (Cch) (100 μM), and angiotensin II (Ang-II) (0.5 μM) (Figure S3A). All three agonists induced Ca2+ increases in a concentration-dependent manner (Figure S3B). Low D values of kinetic parameters (time to peak: D = 0.09–0.24; decay: D = 0.07–0.3; duration: D = 0.09–0.28) and low to moderate D values of number of events within ROI (D = 0.02–0.17) were obtained when measuring differences between NC-SMCs differentiated using protocols A and B (Figure S3C). Comparison of Ca2+ responses in NC-SMCs differentiated from independent hiPSC lines showed low to moderate D values of kinetic parameters of MP (time to peak: D = 0.11–0.27; decay: D = 0.16–0.43; duration: D = 0.15–0.44), kinetic parameters of SPs (time to peak: D = 0.07–0.26; decay: D = 0.11–0.33; duration: D = 0.14–0.34), and number of events within ROI (D = 0.02–0.2) (Figure S3D).
Differences in kinetic parameters of Ca2+ MP initiated by ET-I, Cch, and Ang-II were observed in NC-SMCs differentiated from the FLB243 hiPSC line (ET versus Cch: D = 0.13–0.41; ET versus Ang-II: D = 0.28–0.65; Cch versus Ang-II: D = 0.16–0.59), and to a lesser extent NC-SMCs differentiated from the NCRM1 hiPSC line (ET versus Cch: D = 0.18–0.37; ET versus Ang-II: D = 0.29–0.51; Cch versus Ang-II: D = 0.11–0.24) (Figure S3E). NC-SMCs differentiated from the LUMC054 hiPSC line showed comparable kinetic parameters of Ca2+ MP by various vasoconstrictors (ET versus Cch: D = 0.2–0.3; ET versus Ang-II: D = 0.14–0.24; Cch versus Ang-II: D = 0.16–0.24) (Figure S3E). These variations were not observed in SPs in all hiPSC lines (ET versus Cch: D = 0.06–0.3; ET versus Ang-II: D = 0.05–0.28; Cch versus Ang-II: D = 0.07–0.34) (Figure S3E). Importantly, NC-SMCs differentiated with protocol B showed higher variability in number of events within ROI in contrast to protocol A (protocol A: D = 0.02–0.14; protocol B: D = 0.05–0.25) (Figure S3E).
Relative cell-surface area decrease upon stimulation with ET-I (0.1 μM) in NC-SMCs differentiated from three independent hiPSC lines with protocols A or B and showed low D values (protocol A: D = 0.12–0.18; protocol B: D = 0.13–0.16) (Figures S4A–S4C). NC-SMCs differentiated using protocol A showed slightly greater relative cell-surface area decreases (Figure S4A).
Discussion
Since vSMCs are highly heterogeneous and may differ in developmental origin, we focused on the neural crest population, which has been shown previously to be a major source of vSMCs in the cerebral vasculature. Accordingly, we chose HBVPs and HBVSMCs as a primary human perivascular cell type of neural crest origin as a comparator. We successfully obtained NCCs and derivative NC-SMCs from three independent hiPSC lines using methods based on previously published protocols. We analyzed large ensembles of these NC-SMCs in Ca2+ and contraction assays and compared their responses with HBVP and HBVSMC outputs.
We observed that NC-SMCs differentiated with protocols A, B, or E were most like HBVSMCs in the Ca2+ assay in exhibiting SPs, albeit with slower kinetics of Ca2+ release and reuptake. NC-SMCs differentiated with protocols A and E showed the highest relative cell-surface area decrease upon contraction among all hiPSC-derived NC-SMCs. Although NC-SMCs differentiated with protocol E appeared more similar to HBVSMCs based on Ca2+ release and contractile behavior, their differentiation took much longer and included high concentrations of fetal bovine serum while protocol A was shorter and serum free. Thus, when contractile phenotypes are required, we concluded that protocol A is fit for purpose. On the other hand, NC-SMC differentiation with protocols C and D results in cells functionally closer to HBVPs, although expression of contractile SMC markers was higher compared with HBVPs. Importantly, these assays produced a wide range of detailed information on the vSMC response to stimuli, providing useful information to characterize the hiPSC-derived cells, select the most appropriate protocol, and thus ensure that the vSMCs are fit for purpose in downstream assays.
In summary, we have provided an unambiguous method for functional analysis of hiPSC-vSMCs that provides multiple parameters to accurately access phenotype in the overall cell population, including heterogeneity in Ca2+ and contractile responses across NC-SMCs differentiated from different hiPSC lines. This overcomes one major limitation of the efficient use of vSMCs in current studies, namely the lack of specific protein or genetic markers that distinguish perivascular cell types. As many disease states involve switches in contractile phenotype and differential responses to vasoconstrictor stimuli, we expect the methodology to provide a robust approach for quantification and specification of vSMC functionality.
Experimental Procedures
Full details are provided in Supplemental Experimental Procedures.
hiPSC Maintenance
hiPSCs were cultured on Matrigel-coated plates in mTeSR-1 or recombinant vitronectin-coated plates in TeSR-E8 all from STEMCELL Technologies, according to the manufacturer's instructions.
Data Analysis
Intracellular Ca2+ Release
Images were processed using a freely available plugin “LC Pro” for ImageJ (Francis et al., 2012). Free open-source CellProfiler software (Carpenter et al., 2006) was used to determine the total number of cells in a field of view. Output data were analyzed using a customized R-based script. MP was defined as the first Ca2+ release that took place within ∼100 s after administration of the vasoconstrictor. SPs were defined as Ca2+ events after MP if two or more peaks were detected within a given ROI.
Contraction
Images were processed using a customized pipeline that included automated cell identification and tracking using CellProfiler. Output data were analyzed using a customized R-based script. Contraction was defined as a percentage of cell-surface area decrease (Equations 1 and 2):
(Equation 1) |
(Equation 2) |
where i is the tracking index number of a single cell; , , and are cell-surface area measured from pre-stimulated, negative control, and post-stimulated states, respectively.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism 7 software. The data are reported as mean ± SD. D-metrics was used to measure the difference between two population histograms as a discrete estimator of Kullback-Leibler divergence and calculated using Equation 3:
(Equation 3) |
where n is total number of bins.
Author Contributions
O.V.H. designed and performed research, analyzed and interpreted results, and wrote the manuscript; A.C. analyzed and interpreted results and edited the manuscript; F.E.v.d.H. performed real-time PCRs; C.L.M. designed the research, interpreted results, and edited the manuscript; V.V.O. designed the research, interpreted results, and wrote the manuscript.
Acknowledgments
We would like to thank Peter ten Dijke for providing TGF-β3 and useful discussions, Martino Morella for help with ImageJ plugins, and Leon G.J. Tertoolen, Luca Sala, and Berend J. van Meer for discussions on Ca2+ and contraction. This project received funding from the European Union's Horizon 2020 Framework Program (668724); European Research Council (ERCAdG 323182 STEMCARDIOVASC); and the European Union's Horizon 2020 and innovation program under the Marie Skłodowska-Curie grant agreement no. 707404.
Published: March 7, 2019
Footnotes
Supplemental Information includes Supplemental Experimental Procedures, four figures, and two videos and can be found with this article online at https://doi.org/10.1016/j.stemcr.2019.02.003.
Supplemental Information
References
- Borysova L., Wray S., Eisner D.A., Burdyga T. How calcium signals in myocytes and pericytes are integrated across in situ microvascular networks and control microvascular tone. Cell Calcium. 2013;54:163–174. doi: 10.1016/j.ceca.2013.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cheung C., Bernardo A.S., Trotter M.W.B., Pedersen R.A., Sinha S. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat. Biotechnol. 2012;30:165–173. doi: 10.1038/nbt.2107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cheung C., Goh Y.T., Zhang J., Wu C., Guccione E. Modeling cerebrovascular pathophysiology in amyloid-β metabolism using neural-crest-derived smooth muscle cells. Cell Rep. 2014;9:391–401. doi: 10.1016/j.celrep.2014.08.065. [DOI] [PubMed] [Google Scholar]
- Dash B.C., Levi K., Schwan J., Luo J., Bartulos O., Wu H., Qiu C., Yi T., Ren Y., Campbell S. Tissue-engineered vascular rings from human iPSC-derived smooth muscle cells. Stem Cell Reports. 2016;7:19–28. doi: 10.1016/j.stemcr.2016.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Francis M., Qian X., Charbel C., Ledoux J., Parker J.C., Taylor M.S. Automated region of interest analysis of dynamic Ca2+ signals in image sequences. Am. J. Physiol. Cell Physiol. 2012;303:C236–C243. doi: 10.1152/ajpcell.00016.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fukuta M., Nakai Y., Kirino K., Nakagawa M., Sekiguchi K., Nagata S., Matsumoto Y., Yamamoto T., Umeda K., Heike T. Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. PLoS One. 2014;9:e112291. doi: 10.1371/journal.pone.0112291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Granata A., Serrano F., Bernard W.G., McNamara M., Low L., Sastry P., Sinha S. An iPSC-derived vascular model of Marfan syndrome identifies key mediators of smooth muscle cell death. Nat. Genet. 2017;49:97–109. doi: 10.1038/ng.3723. [DOI] [PubMed] [Google Scholar]
- Hackland J.O.S., Frith T.J.R., Thompson O., Navarro A.M., Garcia-Castro M.I., Unger C., Andrews P.W. Top-down inhibition of BMP signaling enables robust induction of hpscs into neural crest in fully defined, xeno-free conditions. Stem Cell Reports. 2017;9:1043–1052. doi: 10.1016/j.stemcr.2017.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huang M., Miller M.L., McHenry L.K., Zheng T., Zhen Q., Ilkhanizadeh S., Conklin B.R., Bronner M.E., Weiss W.A. Generating trunk neural crest from human pluripotent stem cells. Sci. Rep. 2016;6:1–9. doi: 10.1038/srep19727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- James L.R., Andrews S., Walker S., de Sousa P.R.S., Ray A., Russell N.A., Bellamy T.C. High-throughput analysis of calcium signalling kinetics in astrocytes stimulated with different neurotransmitters. PLoS One. 2011;6 doi: 10.1371/journal.pone.0026889. e26889–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee G., Kim H., Elkabetz Y., Al Shamy G., Panagiotakos G., Barberi T., Tabar V., Studer L. Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells. Nat. Biotechnol. 2007;25:1468–1475. doi: 10.1038/nbt1365. [DOI] [PubMed] [Google Scholar]
- Leung A.W., Murdoch B., Salem A.F., Prasad M.S., Gomez G.A., Garcia-Castro M.I. WNT/β-catenin signaling mediates human neural crest induction via a pre-neural border intermediate. Development. 2016;143:398–410. doi: 10.1242/dev.130849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Majesky M.W. Developmental basis of vascular smooth muscle diversity. Arterioscler. Thromb. Vasc. Biol. 2007;27:1248–1258. doi: 10.1161/ATVBAHA.107.141069. [DOI] [PubMed] [Google Scholar]
- Menendez L., Yatskievych T.A., Antin P.B., Dalton S. Wnt signaling and a Smad pathway blockade direct the differentiation of human pluripotent stem cells to multipotent neural crest cells. Proc. Natl. Acad. Sci. U S A. 2011;108:19240–19245. doi: 10.1073/pnas.1113746108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ng E.S., Davis R., Stanley E.G., Elefanty A.G. A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 2008;3:768–776. doi: 10.1038/nprot.2008.42. [DOI] [PubMed] [Google Scholar]
- Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004;84:767–801. doi: 10.1152/physrev.00041.2003. [DOI] [PubMed] [Google Scholar]
- Sinha S., Santoro M.M. New models to study vascular mural cell embryonic origin: implications in vascular diseases. Cardiovasc. Res. 2018;36:481–491. doi: 10.1093/cvr/cvy005. [DOI] [PubMed] [Google Scholar]
- Wanjare M., Kuo F., Gerecht S. Derivation and maturation of synthetic and contractile vascular smooth muscle cells from human pluripotent stem cells. Cardiovasc. Res. 2013;97:321–330. doi: 10.1093/cvr/cvs315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wanjare M., Kusuma S., Gerecht S. Defining differences among perivascular cells derived from human pluripotent stem cells. Stem Cell Reports. 2014;2:561–575. doi: 10.1016/j.stemcr.2014.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wray S., Burdyga T., Noble K. Calcium signalling in smooth muscle. Cell Calcium. 2005;38:397–407. doi: 10.1016/j.ceca.2005.06.018. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.